Patient specific instrumentation: added cost with no proven value or an evolving technology to raise outcomes and improve OR efficiencies? This very timely debate pits two great surgeon/scientists against each other and in the process sheds light and understanding on this critical issue.
Podcast Features & News
The Great CCJR Debates
OK, it’s a distal femoral peri-prosthetic fracture. Do you reach for the locking plates, the screws or the intramedullary nails? Or do you opt for a mega prosthesis? This week’s Orthopaedic Crossfire® debate tackles this excellent subject with ENDO-Klinik’s Gehrke choosing the big implant and Orlando Health’s Haidukewych going ORIF. Who wins? You judge.
Unicompartmental Knee or Total Knee? What’s not to like about preserving natural kinematics, lower infection rate and good post op range of motion? But can the patient live with higher revision rates? Dr. Thienpont argues for Uni while Dr. Ranawat takes the counter position. Great and timely debate this week.
Same day total knee arthroplasty is the siren song of large joint reconstruction. Michael Berend has performed over 2, 000 knee arthroplasties with 98% of these folks going home the same day and recommends it strongly. Michael Dunbar points out that these are select patients in a tightly controlled environment. Hard to duplicate especially with heavier, more diabetic and older patients. Read this very interesting debate here.
Gonzalez Della Valle v. Gross: Extensive Acetabular Bone Loss: Impaction Grafting, a Preferred Solution
Acetabular bone loss and impaction grafting, for which patients is it good strategy, which patients is it a ‘no-way’ strategy and is it overly technique dependent? Alejandro Gonzalez Della Valle and Allan Gross, with Daniel Berry moderating, tackle this important and impactful (pun intended) subject.
Open reduction internal fixation or total hip arthroplasty for younger (50-60 years old) patients with displaced femoral neck fractures? This week’s debate pits George Haidukewych against Edwin Su. Who wins? You do…with an outstanding debate.
Is the use of ceramic-on-ceramic in young patients the new standard of care? Yes, says Lee. In fact c-on-c has better wear, is more reliable and provides more options. Not so fast says Schmalzried. Survivorship and function are no better, there is a squeaking and fracture risk. Who wins this debate? You be the judge.
Anterior hip arthroplasty. Is it really better, faster and cheaper or is that mere marketing hype? This week’s debate pits William J. Hozack, M.D. against Fares Haddad, M.B., F.R.C.S. with Paul Lachiewicz moderating on this hot topic. Who wins this most entertaining debate? You be the judge.
Did Tom Sculco get the short straw in this dual mobility THA debate against Steven MacDonald? At one point Moderator Thornhill offered to shield Dr. Sculco from MacDonald’s expected onslaught of data. What really happened? Here’s a clue: Australian Registry! And not much blood on the floor.
Corrosion, adverse tissue reaction, fracture and Australian Registry data. Jacobs and Murphy stir all those concepts up into a hot gumbo of data and case studies. This debate serves up the facts behind distal neck modularity. Bottom line, these guys were for it before they were against it.
Metal on Metal Hip Resurfacing—YES! It is an option for the right patient and surgeon. De Smet v. Dunbar dive into this very interesting, CCJR debate.
Forty years ago Charnley raised the issue of pulmonary embolism risk. This remains a significant concern for surgeons. This excellent debate from CCJR brings us fully up to date on the latest thinking, studies and advice.
Does a patient’s age determine whether to use ceramic-on-ceramic THA? As we saw with the excellent 2013 CCJR debate regarding ceramic-on-ceramic, this is a popular topic. This year Stephen Murphy reminds us that “ceramic-on-ceramic bearings have excellent results” while William Maloney points out that they are not a standard of care and can squeak. Lieberman moderates yet another terrific CCJR debate.
The incidence of femoral neck fractures continues to increase. What’s the best approach for the under 60 patient? George Haidukewych makes the case for open reduction internal fixation (ORIF) while Edwin Su counters with arthroplasty. Who wins? We think the reader.
Dual mobility is the new kid on the block for total hip arthroplasty but it’s not for everyone. John Callaghan reminds us that the constrained liners can work well, especially in older patients while Craig Della Valle argues that constrained liners have metal rings that can break. What’s the right answer? This week’s debate may have found it. Read on.
“Are you doing the anterior approach?” According to Bill Maloney, that’s the most common patient question he gets. But not everyone should follow the anterior siren song. Paul Beaule makes a strong case for the benefits of the anterior approach while Dr. Maloney reminds us that the learning curve is steep. This may be one of the most important debates of the year.
Cobalt chrome or ceramic heads? Steven MacDonald takes the position that there is NO difference between the two in outcomes while Michael Meneghini is very persuasive saying that outcomes are clearly better with cobalt chrome. Who wins this outstanding debate? With mounting evidence of corrosion from cobalt chrome, this is a timely debate.
Patient Specific Instrumentation (PSI), unproven value or next new thing for knee replacement surgery? Dr. Barrack says he’s tried it and it didn’t improve outcomes or value. Dr. Pagnano counters by saying that in his experience PSI lowers stress in the OR and is valuable for certain hospitals. Another timely and important debate from CCJR.
All poly tibia knees? Really? Get ready to be surprised. Says David Lewallen MD “Poly designs are cost effective and an excellent solution for a subset of patients.” Taking the opposite point of view is Leo Whiteside MD saying; “Well David, I wish I could agree with you but then we’d both be really wrong.” Welcome to an especially fun and informative debate.
According to Robert Barrack, M.D.” There are about five things that can happen when you resurface a patella and four of them are bad.” Not so, says Wayne Paprosky, M.D. in this spirited CCJR debate. “I say resurface the patella” With modern techniques and instruments “Just go ahead and resurface the patella. Why not finish the job?” Who wins this debate? You be the judge.
“I believe that we are on the threshold of the cementless total knee coming of age, ” says Louis Kwong. Not so fast counters Mark Pagnano, “It’s my contention that in 2015 cemented fixation remains the gold-standard for total knee arthroplasty fixation.” Who’s right? In this spirited debate it’s truly hard to tell.
Why replace the total knee when your patient only has medial arthritis? Fares Haddad goes toe-to-toe with Thomas Sculco over TKA versus UNI when the issue is medial compartment arthritis. Is TKA the only tried and true solution? You be the judge.
Them’s fighting words! Measured resection or gap balancing in total knee arthroplasty. Aaron Hofmann M.D. makes a strong case for measured resection but Bryan Springer M.D. counters effectively for gap balancing. Who earns an “A”? You be the judge.
Lynn Crosby: “When treating cuff tear arthropathy with loss of acromial-humeral distance; pain with or without activity; good deltoid tone and strength, reverse is the best option. Not so fast, says Reuben Gobezie: “Don’t do these reverse replacements on patients who have these types of tears because they have pre-op range of motion greater than 90. It is not a good outcome.” Who wins this great debate? You decide.
In the Crossfire this week is a very sticky topic—cementing that shoulder replacement. Says John W. Sperling “If we look over all the literature one can see that cement fixation is frankly not necessary.” Not so fast says William H. Seitz, Jr., “Cement has become the gold standard and there are new designs and new techniques and we also have new techniques for cementing as well.” It’s a lively and informative debate, for sure.
To Surface Replace or Not to Surface Replace. That is the question. Buz Burkhead and Anthony Romeo debate fiercely the advisability of shoulder surface replacements when there is a Hills-Sachs lesion. It’s a spirited intellectual tussle which we think you’ll enjoy immensely.
“Twenty-five years of implant retrieval has shown that we definitely have a solid attachment with cementless devices, ” argues Aaron Hofmann. Aaron Rosenberg counters, “The literature and registries clearly show that it sometimes is just silly not to cement (patients with osteopenia, patients with significant bone defects, the elderly).”
“There are higher complications and mortality with simultaneous bilateral total knee surgery (SBTKA), ” argues Jay Parvizi, “it is for a select group of patients.” Richard Scott counters, “SBTKA is indicated in 10-15% of patients, patient and family satisfaction is high, and recent reports indicate a cost savings and the overall morbidity is less compared to staged procedures.”
“Patient specific TKA—especially in large patients or very small patients—gives a precise fit. It’s easy for the OR staff, the jigs are accurate, and you get excellent intraoperative stability, ” argues Tom Minas. Paul Lachiewicz counters, “Ask yourself three questions: Does it provide better outcomes and decreased revisions for patients? Is it less expensive? Is it easier for the surgeon? For patient specific instrumentation the answer is ‘NO’ to all three.”
“Modular platforms are more expensive, unproven, and you have a rigid implant along with bone stress shielding, ” argues David Lewallen. But Tom Thornhill counters, “You have fewer options with an all poly tibia, including the fact that you can’t go without cement. And if you cemented an all poly tibia you can sometimes miss the fact that there is cement left towards the back.”
A private Brazilian insurance group claims U.S. orthopedic and other implant device makers and the U.S. government allegedly violated the Foreign Corruption Act. In numerous private lawsuits, the group alleges a “Prosthetic Mafia” gorged payers.
In this new era of cost containment in medicine, adding over $1,000 to the cost of a procedure sounds fiscally irresponsible. A group of new studies about post op infection rates provide new insights into this critical issue as contributing commentator, Jay Mabrey, M.D., MBA, CPE explains.
Doctors and patients report rushes for procedures as worries over ACA overhaul spike.
New MIS Spine Study Group Launch; New Study Targets Cellular RA Triggers; Active Implants Names Ted Davis President, CEO
Kern Singh, M.D. is advancing the science of spine with the establishment of the MISSG. New research suggests that we need to look deeper into RA to treat it. Ted Davis, 25-year veteran of life sciences, takes helm at Active Implants.
A new concussion model developed by Gretchen Thomsen, Ph.D., of the Regenerative Medicine Institute at Cedars-Sinai Medical Center in Los Angeles and colleagues triggered earlier onset of familial Amyotrophic Lateral Sclerosis symptoms. The researchers hope that the model can be used to develop novel therapies.
According to their colleagues, these are the leading orthopedic hand surgeons in North America. Whether handling the wrist, elbow, or hand, these exemplary physicians have reached the pinnacle of their profession.
Peachtree Orthopedics is the second orthopedic clinic in Atlanta to fall victim to TheDarkOverlord hacking group in 2016. With over half a million patient records held at ransom, with sensitive information leaked in a teaser threat, Peachtree is working with the FBI to prevent patient identity theft
Seven months after the DOJ filed a lawsuit to stop the $37B Aetna-Humana merger, along with a complementary Anthem-Cigna merger, a district judge rules in favor of the DOJ—but Aetna promises a quick appeal. What does a potential merger mean for the millions of Medicare Advantage customers who rely on these mega insurers for coverage?
A decade-long legal battle between Zimmer Biomet, the Department of Justice (DOJ), and Securities and Exchange Commission (SEC) ended in a grand finale with a $30.5 million settlement. Allegations include violations of the U.S> Foreign Corrupt Practices Act (FCPA) and improprieties in Brazil and Mexico.
Renowned orthopedic surgeon Dr. Jamie Alexandra Dale is seeking justice and $31 million after she was attacked and left for dead by her ex-boyfriend and former NFL player Curtis Jordan. Her permanent injuries have left her unable to continue her surgery practice. Her story is not only heartbreaking but an indication of the economic toll this attack represented.
Pain Meds and Hearing Loss in Women; Houston Methodist’s New Biomechanics Lab; Implant Corrosion Update
Familiar pain meds are associated with hearing loss in women! Houston Methodist is sporting a new ortho biomechanics lab, complete with state-of-the art motion equipment. And Rush is the only facility in the U.S. with a new technology to tackle implant corrosion.
Which companies will increase shoulder and foot/ankle market share in 2017. In mid-December we received a flashlight into the opaque future of those two dynamic extremity markets. The early Xmas gift came courtesy of top global medical technology analyst, Glenn Novarro. Here is what we learned.
It’s Donald Trump’s world in Washington. The Boss is driving agendas now and here’s the absolutely very latest. The ACA is first up. But there is also a spate of other year-end developments—primarily new digital healthcare initiatives—that should be noted.
Orthopedic surgeon Dr. Tom Price is in charge of implementing President-elect Trump’s promise to repeal and replace Obamacare. He faces a 2, 000 page long law and a Rubik’s Cube of rules and regulations. But he is the right guy for the job having led the Republican effort over the last couple of years to design an alternative plan. Can Obamacare be untwisted? What does it mean for orthopedics? We find out.
It’s not a revolution, but it is changing orthopedics. 3D printing produced the fastest new product launch in Stryker Spine’s history. It also represented 20% of the winning spine technologies for 2016. Stryker’s rousing success with Tritanium has lessons for everyone. Here they are.
NASS new guidance document regarding bone growth stimulators for spine fusion brings clarity to an often confusing gaggle of products and indications. Bottom line, the evidence supports some bone stimulators and not others in spine fusion. Here’s the story.
Robots, 3D printing and clever strategies for navigating the spinal anatomy dominated this year’s winning technologies. Clearly we are in an environment where risk reduction rules. And so our panel selected impressively clever technologies which make every surgeon even more perfect…and awesome. Congratulations to each and every winner!
RBC’s excellent spine surgeon survey, now in its eighth year, was released a couple of weeks ago and it provided many insightful, even surprising, results. Which products are spine surgeons most excited about? What do they think is happening with reimbursement? Is their business growing or declining? Here are RBC’s answers.
A new, data driven tool which cuts patient assessment time from weeks to, literally, 30 seconds is the hot new technology for professional athletes. Eventually, maybe sooner, it will be coming to a large joint clinic near you. Maybe your clinic. This innovation feels like a game changer. It measures muscle health and therefore rehab milestones and progress.
The hype surrounding Zimmer Biomet’s Vanguard ID had us double checking with our surgeon friends. They told us this is actually a particularly interesting innovation in total knee arthroplasty. Apparently, the venerable Vanguard knee is still capable of a few new tricks. Here’s what we learned.
Midwest Orthopaedics at Rush is welcoming five new physicians! New research from Australia is re-examining an old vertebroplasty debate. ZendyHealth and Kerlan-Jobe have teamed up to offer a “name your price” surgery option.
Is chemonucleolysis for painful lower back disc herniation returning? In the 1980s chymopapain achieved fairly wide spread use as a chemonucleolysis agent. Outcomes were highly technique and patient selection dependent. It eventually left the market. Now two large firms have inked a deal to bring a new chemonucleolysis approach to market. Will this one work?
Medical marijuana is the law in 23 states, 1.2 million marijuana cards have been issued and the two most common reasons for getting a medical marijuana card are back and arthritis pain. How should orthopedists in those states deal with the phenomenon of medical marijuana? We have some answers.
In the exam room, OR, or the research lab, these are some of the top sports knee surgeons in North America.
New JBJS study offers an intriguing look at an extended release steroid injection for knee pain. Authors Bodick, Lufkin and Kumar report that extended release triamcinolone acetonide (TCA) prolongs and amplifies pain relief in arthritic knees.
From the late 1990s to today, the number of annual deaths from preventable medical errors has increased roughly four-fold. What is going on? Former head of patient safety at AAOS tackles this troubling statistic head on and discusses new efforts to stem the rising tide of adverse surgical events in the U.S.
DePuy Synthes’ new U.S. President Juan-José Gonzalez sat down with OTW recently and painted a picture of an invigorated DePuy Synthes. It’s a vision that wraps the implant in a blanket of services and digitized intelligence. Where’s DePuy Synthes heading? Into a most interesting future. Check it out.
Legendary private investment firm Stephens Group, LLC has made the leap into spine. Earlier this year another major private equity firm, Kohlberg & Company also put their considerable resources behind a small spine company. Stephens is investing in CoreLink, a relatively unknown St. Louis based manufacturer. What’s going on?
The Big Five private insurance carriers—you know who they are—want to consolidate into the Big Three. The U.S. Department of Justice has sued to block them. The American Medical Association agrees and says that if the DOJ fails, private health insurance in America will be forever changed. For the worse. Hard to disagree.
Invibio was the first provider of PEEK to obtain an FDA Master File. The product was a game changer. According to the FTC, the company then tried to create a monopoly by locking up customers with exclusivity contracts. When competitors tried to enter, they were blocked. The FTC filed a lawsuit. The company agreed to a Consent Decreed. Will the monopoly end?